These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 8613602)

  • 1. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy.
    Kono T; Morita H; Nishina T; Fujita M; Hirota Y; Kawamura K; Fujiwara A
    J Am Coll Cardiol; 1996 Mar; 27(4):774-8. PubMed ID: 8613602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian variation in the efficacy of tissue-type plasminogen activator.
    Kurnik PB
    Circulation; 1995 Mar; 91(5):1341-6. PubMed ID: 7867171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
    J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
    J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aortic counterpulsation may improve late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy.
    Kono T; Morita H; Nishina T; Fujita M; Onaka H; Hirota Y; Kawamura K; Fujiwara A
    J Am Coll Cardiol; 1996 Oct; 28(4):876-81. PubMed ID: 8837563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
    von Hodenberg E; Kreuzer J; Hautmann M; Nordt T; Kübler W; Bode C
    Am J Cardiol; 1991 Jun; 67(16):1349-53. PubMed ID: 1828324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Califf RM; Ellis SG; Sigmon KN; Lee KL; Leimberger JD; Topol EJ
    J Am Coll Cardiol; 1993 Dec; 22(7):1780-7. PubMed ID: 8245328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
    Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
    J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of different start time of urokinase therapy after acute myocardial infarction efficacy of thrombolysis. The Collaborative Research Group on Thrombolysis.
    Chin Med J (Engl); 1997 Jan; 110(1):47-9. PubMed ID: 9594321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Topol EJ; Califf RM; Sigmon KN; Lee KL; Ohman EM; Rosenschein U; Ellis SG
    Am J Cardiol; 1995 May; 75(14):871-6. PubMed ID: 7732992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
    Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
    Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
    Zahger D; Karagounis LA; Cercek B; Anderson JL; Sorensen S; Moreno F; Shah PK
    Am J Cardiol; 1995 Oct; 76(11):749-52. PubMed ID: 7572648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction: a multivariate analysis.
    de Chillou C; Riff P; Sadoul N; Ethevenot G; Feldmann L; Isaaz K; Simon JP; Boursier M; Khalifé K; Thisse JY; Aliot E
    J Am Coll Cardiol; 1996 Jun; 27(7):1662-8. PubMed ID: 8636551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical implications of circadian variations in thrombolytic and antithrombotic activities.
    Kurnik PB
    Cardiol Clin; 1996 May; 14(2):251-62. PubMed ID: 8724557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.